BeOne Medicines teams with Revolution Medicines on RAS cancer drug development, Asia rights deal
RVMD•Asia rights and trial responsibilities
BeOne received exclusive rights in select Asian markets to develop or commercialize those four assets, while Revolution retained rights outside the territory.
BeOne will fund and run a global registrational Phase 3 trial for one of the RAS(ON) inhibitors.
Revolution is eligible for development and sales milestones, plus tiered royalties on partnered-region net sales.
BeOne and Revolution Medicines enter RAS(ON) collaboration
BeOne Medicines AG entered a multi-part collaboration with Revolution Medicines covering clinical development and regional commercialization for RAS(ON) cancer drugs.
The partners will test combination regimens pairing select BeOne oncology assets with Revolution’s four clinical-stage RAS(ON) inhibitors.
